MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/rheumatology/kead426

Медицинская библиотека · Rheumatology (Oxford, England) · 2024

Efficacy and management of tocilizumab in polymyalgia rheumatica: results of a multicentre retrospective observational study.

Assaraf Morgane, Chevet Baptiste, Wendling Daniel, Philippe Peggy, Cailliau Emeline, Roux Christian, Dieude Philippe, Ottaviani Sebastien, Avouac Jérôme, Delacour Mathilde, Houvenagel Eric, Sellam Jérémie, Cortet Bernard, Henry Julien, Flipo René-Marc, Devauchelle-Pensec Valérie

СтатьяМногоцентровое исследованиеНаблюдательное исследованиеПеревод в очереди

Аннотация

OBJECTIVES

The efficacy of anti-IL-6 receptors such as tocilizumab (TCZ) was demonstrated in patients with PMR in two recent randomized controlled trials. The objective of this multicentre retrospective study was to assess the efficacy of TCZ in PMR patients requiring glucocorticoid (GC)-sparing treatment, as well as different strategies for TCZ withdrawal.

METHODS

We conducted a multicentre study in French tertiary healthcare departments for patients with PMR. PMR patients receiving off-label TCZ between 2015 and 2022 were included. The primary endpoint was the proportion of patients tapering to GCs ≤5 mg/day 6 months after the first TCZ infusion. The secondary endpoints were the proportion in whom GC was discontinued during follow-up, and the proportion of patients in whom TCZ was discontinued.

RESULTS

Fifty-three PMR patients were included. Thirty-one patients suffered from active PMR despite conventional synthetic DMARDs. GCs were ≤5 mg/day in 77% of the patients (95% CI 36-89) at 6 months, and in 97% of the patients at 12 months. Six and 12 months after the first TCZ infusion, the proportions of GC-free patients were 22.5% (95% CI 12.7-37.8) and 58.3% (95% CI 43.2-74.1), respectively. Among TCZ withdrawal strategies, TCZ infusion spacing and TCZ dose reduction were more successful (success in 87% and 79% of attempts, respectively) than TCZ discontinuation (success in 52% of attempts; P = 0.012 and P = 0.039, respectively).

CONCLUSION

In GC-dependent PMR patients, treatment with TCZ led to a drastic decrease in GC dose and remission of PMR. TCZ dose reduction or TCZ infusion spacing are good options to consider in TCZ withdrawal.

Для цитирования: Assaraf Morgane, Chevet Baptiste, Wendling Daniel, Philippe Peggy, Cailliau Emeline, Roux Christian, Dieude Philippe, Ottaviani Sebastien, Avouac Jérôme, Delacour Mathilde, Houvenagel Eric, Sellam Jérémie, Cortet Bernard, Henry Julien, Flipo René-Marc, Devauchelle-Pensec Valérie. Efficacy and management of tocilizumab in polymyalgia rheumatica: results of a multicentre retrospective observational study.. Rheumatology (Oxford, England). 2024. DOI: 10.1093/rheumatology/kead426.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.